Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Aurinia Pharmaceuticals Inc (AUPH)

NASDAQ
Currency in USD
Disclaimer
5.030
-0.060(-1.18%)
Closed
After Hours
5.0300.000(0.00%)

AUPH Comments

Trying to get those options out of money. lol!
shorts running out of powder?
Shorts have strong conviction. Could gamma squeeze this week? I would like to see it. OOO AAAH
shorts. lol!!!!
BOOM!
triple witching, $20 options close to being in the money, high short interest. Something to watch!
so should I continue holding?
 absolutely!
Friday fun day!
margin calls ******
T/A will go away and F/A will take over on this one or a BO. Either way she going up.
popcorn for breakfast! YES!!!
Calm before the storm.
Shorts are really rolling the dice here. lol
shorts might be in trouble here. Push $20 and it will run.
Buyout coming, waiting for 30+
30+? What is your reasoning for that share price?
Looking strong!
gamma gamma gamma
BOOM!
Squeeze!!!
Nice movement. Shorts should exit. lol!
Acquisition happening! ⚡⚡🚀🚀
nice surprise in revenues. Could double/triple within 24 months imo.
beautiful!
AUPH reported positive data as competitors 'stumble,' says H.C. Wainwright analyst Ed Arce noted that (AUPH) announced that a "supportive interim analysis" of its AURORA 2 study will be presented at EULAR, held June 2-5. The new data will represent the longest-available outcomes data for LUPKYNIS to date for the treatment of lupus nephritis, or LN, said Arce. Meanwhile, competitor Boehringer Ingelheim announced in a poster presentation at EULAR that its anti-CD40 mAb, BI655064, failed to meet its primary endpoint of complete renal response and Eli Lilly (LLY) disclosed in a recent quarterly filing that TULIP-LN1, its Phase 2 study of anifrolumab, also failed to meet its primary endpoint, according to Arce. The analyst, who maintains his 100% odds of approval view for LUPKYNIS in the U.S., keeps a Buy rating and $35 price target on Aurinia shares. AUPH LLY
oh she is showing some life! Go Aurinia
Turning point is 12.50-60 , buy heavy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.